LT3609529T - Rnr, skirta autoimuninių ligų gydymui - Google Patents

Rnr, skirta autoimuninių ligų gydymui

Info

Publication number
LT3609529T
LT3609529T LTEPPCT/EP2018/059188T LT18059188T LT3609529T LT 3609529 T LT3609529 T LT 3609529T LT 18059188 T LT18059188 T LT 18059188T LT 3609529 T LT3609529 T LT 3609529T
Authority
LT
Lithuania
Prior art keywords
rna
treatment
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
LTEPPCT/EP2018/059188T
Other languages
English (en)
Inventor
Ugur Sahin
Sebastian Kreiter
Christina KRIENKE
Jutta PETSCHENKA
Lena Mareen Kranz
Mustafa DIKEN
Original Assignee
BioNTech SE
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical BioNTech SE
Publication of LT3609529T publication Critical patent/LT3609529T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/EP2018/059188T 2017-04-11 2018-04-10 Rnr, skirta autoimuninių ligų gydymui LT3609529T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/058651 WO2018188730A1 (en) 2017-04-11 2017-04-11 Rna for treatment of autoimmune diseases
PCT/EP2018/059188 WO2018189193A1 (en) 2017-04-11 2018-04-10 Rna for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
LT3609529T true LT3609529T (lt) 2021-10-25

Family

ID=58632945

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/059188T LT3609529T (lt) 2017-04-11 2018-04-10 Rnr, skirta autoimuninių ligų gydymui

Country Status (23)

Country Link
US (2) US11701413B2 (lt)
EP (2) EP3609529B1 (lt)
JP (3) JP7078641B2 (lt)
KR (2) KR102824942B1 (lt)
CN (2) CN118161602A (lt)
AU (1) AU2018253352B2 (lt)
BR (1) BR112019020667A8 (lt)
CA (1) CA3059505A1 (lt)
CY (1) CY1124767T1 (lt)
DK (1) DK3609529T3 (lt)
ES (1) ES2893451T3 (lt)
HR (1) HRP20211559T1 (lt)
HU (1) HUE056871T2 (lt)
IL (2) IL269793B (lt)
LT (1) LT3609529T (lt)
MX (1) MX2019012144A (lt)
PL (1) PL3609529T3 (lt)
PT (1) PT3609529T (lt)
RS (1) RS62582B1 (lt)
SG (2) SG11201909520VA (lt)
SI (1) SI3609529T1 (lt)
SM (1) SMT202100572T1 (lt)
WO (2) WO2018188730A1 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
CA3119449A1 (en) * 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
US11547673B1 (en) * 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN115232825B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的新冠病毒疫苗
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN117750971A (zh) 2021-05-26 2024-03-22 易姆赛斯股份公司 治疗或预防自身免疫病的方法
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
CN118369335A (zh) * 2022-01-06 2024-07-19 上海吉量医药工程有限公司 N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
SI3112467T1 (en) 2009-12-07 2018-06-29 The Trustees Of The University Of Pennsylvania Rna preparations comprising purified modified rna for reprogramming cells
WO2012154933A1 (en) * 2011-05-10 2012-11-15 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
US20150044244A1 (en) * 2011-09-30 2015-02-12 Beijing Advanccine Biotechnology Co. Ltd. Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases
EP3421601B1 (en) 2011-12-30 2019-12-04 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
WO2013120498A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN106395552B (zh) * 2015-08-03 2020-03-17 奥的斯电梯公司 无绳电梯系统导轨组件
WO2017036889A1 (en) * 2015-08-28 2017-03-09 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of rna
KR102378404B1 (ko) 2016-04-22 2022-03-24 비온테크 에스이 단일가닥 rna 제공 방법
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases

Also Published As

Publication number Publication date
AU2018253352B2 (en) 2025-04-10
SI3609529T1 (sl) 2021-11-30
EP3981424A1 (en) 2022-04-13
IL269793A (en) 2019-11-28
MX2019012144A (es) 2019-11-21
EP3609529A1 (en) 2020-02-19
SG11201909520VA (en) 2019-11-28
ES2893451T3 (es) 2022-02-09
US20230330198A1 (en) 2023-10-19
RU2019135808A (ru) 2021-05-11
CN110719787A (zh) 2020-01-21
KR102824942B1 (ko) 2025-06-25
RU2019135808A3 (lt) 2021-08-10
WO2018188730A1 (en) 2018-10-18
KR20240042138A (ko) 2024-04-01
US11701413B2 (en) 2023-07-18
KR20190134765A (ko) 2019-12-04
SMT202100572T1 (it) 2021-11-12
JP2024059794A (ja) 2024-05-01
RS62582B1 (sr) 2021-12-31
DK3609529T3 (da) 2021-10-11
CN118161602A (zh) 2024-06-11
EP3609529B1 (en) 2021-09-08
JP7078641B2 (ja) 2022-05-31
IL290980A (en) 2022-05-01
CN110719787B (zh) 2024-03-15
JP2020516658A (ja) 2020-06-11
HUE056871T2 (hu) 2022-04-28
CY1124767T1 (el) 2022-11-25
PL3609529T3 (pl) 2021-12-13
CA3059505A1 (en) 2018-10-18
PT3609529T (pt) 2021-10-14
AU2018253352A1 (en) 2019-10-17
JP7444924B2 (ja) 2024-03-06
BR112019020667A8 (pt) 2022-08-16
JP2022110127A (ja) 2022-07-28
BR112019020667A2 (pt) 2020-05-05
IL269793B (en) 2022-04-01
SG10202111163VA (en) 2021-11-29
WO2018189193A1 (en) 2018-10-18
US20200061166A1 (en) 2020-02-27
HRP20211559T1 (hr) 2022-01-21

Similar Documents

Publication Publication Date Title
LT3609529T (lt) Rnr, skirta autoimuninių ligų gydymui
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
IL268894A (en) Medical RNA
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
IL269371A (en) Treatment methods
LT3433368T (lt) Trans-replikuojama rnr
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
LT3512863T (lt) 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu
LT3577124T (lt) Nukleotido hemisulfato druska, skirta hepatito c virusui gydyti
SI3612624T1 (sl) Genska terapija
IL269735A (en) Antisense oligonucleotides for the treatment of stargardt disease
EP3498329A4 (en) CARRIER CATHETER
SI3612237T1 (sl) Genska terapija
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
DK3576740T3 (da) Cancerbehandling
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
LT3191514T (lt) Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EP3597225A4 (en) TREATMENT PROCESS
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3329004T3 (da) Terapeutiske oligonukleotider
IL280968A (en) Combination therapy